Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 3

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 1(3)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05976100Phase 1Completed

Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years

Role: lead

NCT05846243Phase 2Completed

Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years

Role: lead

NCT05762523Phase 1Completed

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Role: lead

NCT04780035Phase 3Completed

Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19

Role: lead

NCT04527575Phase 1Completed

Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19

Role: lead

NCT05021016Phase 3Completed

Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above

Role: lead

All 6 trials loaded